Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Sionna Therapeutics, Inc.NASDAQ: SION
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $10.48M rose 88.5% year over year, behind the +106.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 6.2% from the prior quarter. Over 3 fiscal years it compounded at +61.9% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +116.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $10.48M+6.2% QoQ
- Last fiscal yearDec 2025
- $28.72M+116.5% YoY
- LTMMar 2026
- $34.12M+106.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +88.5% | -100.0% | -188.5 pp |
| 1 year | +116.5% | -100.0% | -216.5 pp |
| 3-year CAGR | +61.9% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 28.72M USD
- Year-over-year change
- +116.5%
- 3-year CAGR
- +61.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.72M | +116.5% |
| FY2024 | 2024-12-31 | 13.27M | +36.7% |
| FY2023 | 2023-12-31 | 9.71M | +43.4% |
| FY2022 | 2022-12-31 | 6.77M | — |
Selling, General & Admin vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 selling, general & admin of $34.12M is the lowest of the 11 companies compared; the peer median is $81.92M.
- Its year-over-year change of +106.9% is the 3rd highest of 11, against a peer median of +22.5%.
- Over three fiscal years its annual growth of +61.9% compares with a peer median of +16.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $15.14B | +24248.6% | -5.7% | 5694.1% | |
| LTM Mar 2026 | $356.28M | +23.3% | +63.9% | 83.3% | |
| LTM Mar 2026 | $191.5M | +13.2% | +9.8% | 60.8% | |
| LTM Jun 2026 | $153.89M | +144.6% | +66.0% | — | |
| LTM Jun 2026 | $99.69M | -4.4% | -6.7% | — | |
| LTM Sep 2026 | $64.15M | +52.3% | +47.5% | — | |
| LTM Sep 2026 | $53.4M | -37.3% | +4.7% | 78.7% | |
| LTM Sep 2026 | $51.3M | +21.7% | +17.2% | 45802.7% | |
| LTM Mar 2026 | $42.56M | -1.1% | +23.3% | 196.9% | |
| LTM Mar 2026 | $39.04M | +38.9% | +14.7% | 195.2% | |
| LTM Mar 2026 | $34.12M | +106.9% | +61.9% | — | |
| Peer median (excluding SION) | $81.92M | +22.5% | +16.0% | 195.2% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 647K |
| Gross Profit | 0 | 0 | (668K) | (647K) |
| Gross Margin | — | — | — | — |
| Research & Development | 34.61M | 40.63M | 57.29M | 60.26M |
| Selling, General & Admin | 6.77M | 9.71M | 13.27M | 28.72M |
| Operating Expenses | 41.37M | 50.33M | 69.89M | 88.34M |
| Depreciation & Amortization | 122K | 583K | 668K | 647K |
| EBITDA | (40.12M) | (46.68M) | (61.02M) | (74.62M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (41.37M) | (50.33M) | (70.56M) | (88.98M) |
| Operating Margin | — | — | — | — |
| Interest Income | 1.13M | 2.77M | 8.17M | 13.3M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.13M | 3.07M | 8.87M | 13.71M |
| Income Before Tax | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.91) | (1.07) | (1.40) | (1.88) |
| EPS (Diluted) | (0.91) | (1.07) | (1.40) | (1.88) |
| Weighted Avg Shares | 44.12M | 44.12M | 44.12M | 39.96M |
| Weighted Avg Shares (Diluted) | 44.12M | 44.12M | 44.12M | 39.96M |
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.